No open-market selling at Inhibikase Therapeutics, Inc. in the past year, which is unusual. Instead one insiders bought about $3 million worth of IKT.
Biggest single buyer: SANDS FRANK M., 10% Owner, with roughly $3 million.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters. On the institutional side, 106 funds reported holding IKT at the end of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 24, 2025 | SANDS FRANK M. | 10% Owner | Buy | 2,068,965 | $1.45 | $3.0M | SEC |
| Oct 23, 2024 | Bellini Roberto | Director | Buy | 1,460,000 | $1.37 | $2.0M | SEC |
| Oct 23, 2024 | Kush Arvind | Director | Buy | 145,000 | $1.37 | $199K | SEC |
| Oct 23, 2024 | Munshi Amit | Director | Buy | 365,000 | $1.37 | $500K | SEC |
In the last 12 months Inhibikase Therapeutics, Inc. insiders made open-market purchases worth about $3 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in IKT was filed on 2025-11-24.
106 investment managers reported holding IKT in SEC Form 13F filings for Q2 2026.
No congressional trades in IKT were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).